Drugmakers File 2nd Suit To Thwart Generic Xyzal

Law360, New York (May 29, 2008, 12:00 AM EDT) -- Belgian drugmaker UCB SA and its U.S. partner, Sepracor Inc., have filed their second lawsuit in two months in an effort to stave off a generic challenge to their antihistamine drug Xyzal.

The latest suit, filed Wednesday in the U.S. District Court for the Eastern District of North Carolina, alleges that Sun Pharmaceutical Industries Ltd. infringed the company's patent for levocetirizine dihydrochloride 5 mg tablets by filing an abbreviated new drug application with the U.S. Food and Drug Administration to make and sell generic Xyzal....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.